20 March 2024, Melbourne, Australia: VivaZome Therapeutics Pty Ltd and La Trobe University are pleased to announce that they will be collaborating to explore the therapeutic potential for VivaZome’s extracellular vesicles (EVs) in models of stroke in the laboratory of Professor Chris Sobey (pictured).  This collaborative effort brings together VivaZome’s expertise in EV manufacturing and La Trobe’s stroke research capabilities led by Professor Sobey. The study entitled “Anti-inflammatory exosomes for stroke: a proof-of-concept (PoC) pilot study” is supported by a $300k grant from the La Trobe Proof-of-Concept (PoC) Fund. Click here to read the media release.

VivaZome Therapeutics is pleased to announce that three posters highlighting the company’s strategies and technologies for exosome purification, customisation and manufacturing of extracellular vesicles (“EVs) are being presented at the 6^th annual meeting of the Australian and New Zealand Society of Extracellular Vesicles (“ANZSEV”) this week in the Barossa Valley, South Australia.

Dr David Haylock, CSO of VivaZome, said: “We are delighted to be presenting this work at the ANZSEV meeting as we strive to develop new customised EV-based approaches to treat retinal disease and traumatic brain injury with our esteemed collaborators at Australian National University, The University of Queensland, Cytiva and SeerPharma. These posters highlight the strong progress we are making.”  For the full release, please click here.

To view the poster, “From Laboratory to Manufacturing; Methods and Challenges in Exosome Purification” (Shambrook et al) click here.

For the poster, “Customisation strategies and loading of EVs to treat neurological disease” (Johnston et al), please click here.

For the poster, ”Establishing a robust exosome manufacturing process for translational studies” (Krishna et al), click here.

VivaZome is delighted to announce a suite of positive changes to the company’s board and executive team. Xenia Sango has been promoted to CEO and Managing Director, David Haylock has been appointed as Chief Scientific Officer. and Dr Anthony Filippis has joined the Board as Non-Executive Director. See attached release here (The photo shows Xenia and David in attendance at ISEV 2023 earlier this year)

VivaZome is delighted to announce that two posters with new mice data highlighting the functional potential of extracellular vesicles (“EVs”) will be presented at the annual meeting of the International Society of Extracellular Vesicles (“ISEV”) held on 17-21 May 2023 in Seattle, USA.

The poster, “Local administration of extracellular vesicles from bone marrow-derived mesenchymal stem cells restores homeostatic communication pathways and slows the progression of retinal degeneration” (Wooff et al) is co-authored by scientists from Australian National University (ANU) and VivaZome. The second poster, “Bioengineering exosomes to enhance brain targeting in a mouse traumatic brain injury model” (Chen et al), is co-authored by scientists from The University of Queensland (UQ) and VivaZome.

Dr David Haylock, CEO of VivaZome, said: “We are delighted to be working with world-leading scientists at ANU and UQ as we jointly strive to develop new customised EV-based approaches to treat retinal disease and brain injury”.

See the VivaZome – ANU poster here. See the VivaZome – UQ poster here. Read the full media release here

VivaZome is delighted to have been awarded an Australian Government Round 13 CRC-P grant of $3.0m in support of the 3-year project “Customised exosomes – the future of regenerative medicine”. Joining VivaZome in the CRC-P are five exceptional Australian project partners – La Trobe University, The University of Queensland, Australian National University, Cytiva and SeerPharma. Read the press release here.

VivaZome Therapeutics Pty Ltd has entered into a Memorandum of Understanding (MoU) with The University of Queensland (UQ) focussing on improved therapies for Traumatic Brain Injury (TBI) and post-traumatic epileptogenesis (PTE). TBI afflicts close to 69 million people globally. Under the MoU, VivaZome will collaborate with Professor David Reutens – Director of the Centre for Advanced Imaging (CAI) at UQ – and his colleagues to investigate exosomes for the treatment of TBI and PTE.

Click here to read more

VivaZome Therapeutics has been awarded the top prize in the 2022 Cytiva BioChallenge for the Australia and NewZealand region. The prize, valued at approximately AUD $200,000, will further assist VivaZome in its quest to develop off-the-shelf regenerative medicines. Part of Cytiva’s BioChallenge global series, the inaugural challenge for the ANZ region received 32 applications from various universities and companies. See more here